Impact of systemic therapy on clinical T1 small-cell neuroendocrine carcinoma of the bladder.

ABSTRACT:

Background

The purpose of this study was to analyze survival outcomes and pathologic response of patients with cT1N0 small-cell neuroendocrine carcinoma (SCNEC) of the bladder treated with neoadjuvant chemotherapy (neoCTX).

Materials and methods

All cases of bladder SCNEC treated at our institution from January 1996 to July 2023 were identified. cT1N0 was defined as transurethral resection pathology showing lamina propria invasion with present and uninvolved muscularis propria. Pathologic downstaging and recurrences were evaluated. Disease-free survival (DFS) and overall survival (OS) were analyzed using the Cox regression and Kaplan-Meier method.

Results

A total of 30 patients with cT1N0 bladder SCNEC were included. Median follow-up was 88 months [95% confidence inte

SUBMITTER: Myers AA 

PROVIDER: S-EPMC11550343 | biostudies-literature | 2024 Oct

REPOSITORIES: biostudies-literature